Biotech · Private company
Frequency Therapeutics
Track this companyFree. Adds Frequency Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- FX-322Phase 2 · Hearing Loss, SensorineuralClinicalTrials.gov · fetched Nov 12, 2026
- FX-322Phase 2 · Sensorineural Hearing LossClinicalTrials.gov · fetched Nov 12, 2026
- FX-322 (Four Doses)Phase 2 · Sensorineural Hearing LossClinicalTrials.gov · fetched Nov 12, 2026
- FX-322 (One Dose)Phase 2 · Sensorineural Hearing LossClinicalTrials.gov · fetched Nov 12, 2026
- FX-322 (Two Doses)Phase 2 · Sensorineural Hearing LossClinicalTrials.gov · fetched Nov 12, 2026
- FX-322Phase 1 · PresbycusisClinicalTrials.gov · fetched Nov 12, 2026
- FX-345Phase 1 · Hearing Loss, SensorineuralClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing LossPHASE1 · TERMINATED · started Dec 15, 2022ClinicalTrials.gov NCT05664100 · fetched Nov 12, 2026
- FX-322 in Adults With Acquired Sensorineural Hearing LossPHASE2 · COMPLETED · started Oct 12, 2021ClinicalTrials.gov NCT05086276 · fetched Nov 12, 2026
- FX-322 in Adults With Severe Sensorineural Hearing LossPHASE1 · COMPLETED · started Nov 2, 2020ClinicalTrials.gov NCT04629664 · fetched Nov 12, 2026
- FX-322 in Adults With Age-Related Sensorineural Hearing LossPHASE1 · COMPLETED · started Sep 17, 2020ClinicalTrials.gov NCT04601909 · fetched Nov 12, 2026
- FX-322 in Adults With Stable Sensorineural Hearing LossPHASE2 · COMPLETED · started Oct 4, 2019ClinicalTrials.gov NCT04120116 · fetched Nov 12, 2026
- FX-322 in Sensorineural Hearing LossPHASE1_PHASE2 · COMPLETED · started Jul 3, 2018ClinicalTrials.gov NCT03616223 · fetched Nov 12, 2026